This report presents the IOM Committee on Viral Hepatitis, Community Health Centers Policy and Program: The Federal Perspective: Hepatitis B and C Activities at HRSA, March 3, 2009. It reports on determining ways to reduce new hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and the morbidity and mortality related to chronic viral hepatitis. It reports on the federal perspective on hepatitis B and C activities at HRSA, HRSA vision and goals, factors impacting health disparities, gaps in the current system, and treatment options for HBV and HCV.
This monograph provides an overview of the federal legislative and regulatory processes that support vital hepatitis programs in the United States. It discusses viral hepatitis, its epidemiology in the United States, the responses of various federal bodies, such as funding, programs, and legislation. It provides a list of useful links and resources and documents regarding the unmet needs and challenges of viral hepatitis programs to assist persons interested in advocating for an improved federal response.
This fact sheet explains two analyses published by CDC that examined the severe human and economic burden of sexually transmitted infections (STIs) in the United States. The new estimates indicate that there are about 20 million new U.S. infections each year, half of which occur among the nation’s youth. Also, there are more than 110 million STIs in the United States, which cost the health care system approximately $16 billion in medical costs alone.
This report describes novel HIV screening programs at the Urban Health Plan (UHP), Inc. in New York City and the Interim Louisiana Hospital (ILH) emergency department in New Orleans. Both received startup funding from Gilead Sciences’ HIV on the Frontlines of Communities in the United States (FOCUS) program to implement routine HIV screening. Both programs identified previously undiagnosed HIV infections. Use of the new testing algorithm allowed the New Orleans program to identify antibody-negative acute infections in five (6%) of the 77 patients with newly diagnosed HIV.